Systemic lupus erythematosus laboratory tests

Revision as of 03:25, 15 June 2017 by Mmir (talk | contribs)
Jump to navigation Jump to search

Systemic lupus erythematosus Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Systemic lupus erythematosus from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Lupus and Quality of Life

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Systemic lupus erythematosus laboratory tests On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Systemic lupus erythematosus laboratory tests

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

National Guidelines Clearinghouse

NICE Guidance

FDA on Systemic lupus erythematosus laboratory tests

on Systemic lupus erythematosus laboratory tests

Systemic lupus erythematosus laboratory tests in the news

Blogs onSystemic lupus erythematosus laboratory tests

Directions to Hospitals Treating Systemic lupus erythematosus

Risk calculators and risk factors for Systemic lupus erythematosus laboratory tests

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: {{MIR}

Overview

An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name]
OR
Laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Some patients with [disease name] may have elevated/reduced concentrations of [test], which is usually suggestive of [progression/complication].

Laboratory tests

Lab exam result clinical correlation
Hematology Complete blood count leukopenia

mild anemia

thrombocytopenia

serum creatinine Elevated suggestive of renal dysfunction
Urinalysis with urine sediment hematuria, pyuria, proteinuria, and/or cellular casts
Serology ANA positive in virtually all patients with SLE at some time in the course of their disease If the ANA is positive, one should test for other specific antibodies such as dsDNA, anti-Sm, Ro/SSA, La/SSB, and U1 ribonucleoprotein (RNP)
Antiphospholipid antibodies lupus anticoagulant [LA], IgG and IgM anticardiolipin [aCL] antibodies; and IgG and IgM anti-beta2-glycoprotein [GP]
complement levels C3 and C4 or CH50
Erythrocyte sedimentation rate (ESR)
C-reactive protein (CRP)
Urine protein-to-creatinine ratio
Anti-dsDNA highly specific for SLE

in 70% of patients

anti-Sm antibodies highly specific for SLE

lack sensitivity

in 30% of patients

Anti-Ro/SSA antibodies in 30% of patients

more commonly associated with Sjögren’s syndrome

15593352

anti-La/SSB antibodies in 20% of patients

more commonly associated with Sjögren’s syndrome 15593352

Anti-U1 RNP antibodies in approximately 25 percent of patients with SLE

Not specific, always present in patients with mixed connective tissue disease (MCTD)

15593352

Antiribosomal P protein antibodies high specificity for SLE & low sensitivity for SLE

lack specificity for involvement of a particular organ system or disease manifestation.

If the initial ANA test is negative, but the clinical suspicion of SLE is high, then additional antibody testing may still be appropriate. This is partly related to the differences in the sensitivity and specificity among the methods used to detect ANA.

Laboratory exams to distinguish SLE from other diseases

anti-cyclic citrullinated peptide (CCP) antibodies In patients with predominant arthralgias or arthritis may help exclude a diagnosis of rheumatoid arthritis (RA)

higher specificity for RA and may be more useful for distinguishing the arthritis associated with RA. (See "Biologic markers in the diagnosis and assessment of rheumatoid arthritis", section on 'Rheumatoid factors' and "Biologic markers in the diagnosis and assessment of rheumatoid arthritis

Rheumatoid factor (RF) less diagnostic utility since 20 to 30 percent of people with SLE have a positive RF
Serological studies for infection serologic testing for human parvovirus B19 In patients with a brief history (for example, less than six weeks) of predominant arthralgias or arthritis
serologic testing for hepatitis B virus (HBV) and hepatitis C virus (HCV) in patients with multisystemic clinical findings
serologic studies for Borrelia n areas endemic for Lyme disease
Testing for Epstein-Barr virus (EBV)
Creatine kinase (CK) may reflect myositis, which is relatively uncommon in patients with SLE. Myositis may also suggest an alternative diagnosis such as MCTD, polymyositis (PM), or dermatomyositis (DM).

References

Template:WH Template:WS